1. 藤原俊、加納嘉人、内藤喬浩、青山慧、佐藤信 吾、池田貞勝、森毅彦、末永光邦. Changes in chemotherapy for unresectable or metastatic small bowel adenocarcinoma. 第21 回日本臨床腫瘍学会学術集会 2024.02.22 名古屋国際会議場

  2. Mitsukuni Suenaga, Tetsuo Mashima, Naomi Kawata, Shingo Dan, Hiroyuki Seimiya, Kensei Yamaguchi. Preclinical analysis and clinical validation to identify biomarkers of regorafenib efficacy in patients with metastatic colorectal cancer.. 2024 ASCO GI Cancers Symposium 2024.01.20 SF, US

  1. Mitsukuni Suenaga, Shinichi Yamauchi, Yuya Sato, Rika Noji, Ryo Morikawa, Yoshihito Kano, Masanori Tokunaga, Yusuke Kinugasa. Impact of chemotherapy on COVID-19 vaccination in gastrointestinal cancer patients. 2023 the Japanese Society of Medical Oncology Annual Meeting 2023.03.18 Fukuoka

  2. Satoru Aoyama, Takashi Kamatani, Kousuke Tanimoto, Junko Yokobori, Eriko Takamine, Makiko Egawa, Yuki Kato, Susumu Kirimura, Ichiro Ohnishi, Kouichiro Kimura, Takahiro Asakage, Sadakatsu Ikeda. Case report: Myxofibrosarcoma in the head and neck region with rare TP53 aberration in the background of retinoblastoma.. 2023 the Japanese Society of Medical Oncology Annual Meeting 2023.03.17

  3. Rika Noji,Ryo Morikawa, Takehiko Mori, Hiroyuki Harada, Mitsukuni Suenaga, Yoshihito Kano. Monitoring for Immunotherapy in Head and Neck Cancer by Liquid Biopsy. 2023 the Japanese Society of Medical Oncology 2023.03.17 Fukuoka

  4. Yoshihito Kano, Shingo Sato, Sadakatsu Ikeda, Mitsukuni Suenaga, Takehiko Mori . Establishment of training program for medical oncologist in the era of new medical specialty board system. 2023 the Japanese Society of Medical Oncology 2023.03.17 Fukuoka

  5. Haruko Nakagawa, Satoru Aoyama, Junko Yokobori, Haruhiko Furusawa, Takahiro Mitsumura, Akira Takemoto, Ken Yamagiwa, Masaaki Kawanishi, Sadakatsu Ikeda. A novel Fumarate Hydratase mutation in a patient with lung adenocarcinoma: a case report. 2023 the Japanese Society of Medical Oncology Annual Meeting 2023.03.16

  6. Ryo Morikawa, Kentaro, Shuntaro Yasuda, Rika Noji, Satoru Aoyama, Yoshihito Kano, Shingo Sato, Sadakatsu Ikeda, Masashi Nagata, Takehiko Mori, Mitsukuni Suenaga. Identification of risk factors for gastrointestinal irAEs associated with immune checkpoint inhibitors. 20th the Japanese Society of Medical Oncology Annual Meeting 2023.03.16 Fukuoka

  7. Satoru Aoyama, Ayako Nogami, Sadakatsu Ikeda, Takehiko Mori. Novel protease-mediated double antigen recognizing Chimeric Antigen Receptor (CAR) enhances the directionality of CAR-T cell activity and improves target cell specificity.. Keystone symposia A4: Emerging Cellular Therapies at the Forefront of Cancer Immunotherapy 2023.01.31

  8. Mitsukuni Suenaga, Shinichi Yamauchi, Yuya Sato, Rika Noji, Ryo Morikawa, Yoshihito Kano, Masanori Tokunaga, Yusuke Kinugasa. Impact of chemotherapy on COVID-19 vaccination in patients with gastrointestinal cancer.. 2023 ASCO GI Cancers Symposium 2023.01.21 SF, US

  9. Takeshi Yamada, Nobuhisa Matsuhashi, Takao Takahashi, Keiji Hirata, Takeshi Nagasaka, Yuki Nakamura, Kazuhiro Sakamoto, Keiji Koda, Kazuhiro Hiramatsu, Hiroshi Matsuoka, Hidekazu Kuramochi, Hideyuki Ishida, Kozo Kataoka, Hajime Yokomizo, Yoshinori Kagawa, Mitsukuni Suenaga, Ryo Ohta, Akihisa Matsuda, Hiroshi Yoshida. Impact of RAS and BRAF heterogeneity on the efficacy of EGFR blockade in patients with metastatic colorectal cancer.. 2023 ASCO GI Cancers Symposium 2023.01.21 SF, US

  10. Ryo Morikawa, Kentaro Nitta, Shuntaro Yasuda, Rika Noji, Yoshihito Kano, Shingo Sato, Sadakatsu Ikeda, Masashi Nagata, Takehiko Mori, Mitsukuni Suenaga. Identification of risk factors for gastrointestinal irAEs associated with immune checkpoint inhibitors.. 2023 ASCO GI Cancers Symposium 2023.01.19 SF, US

  1. Satoru Aoyama, Ayako Nogami, Sadakatsu Ikeda, Takehiko Mori. Novel protease-mediated double antigen recognizing Chimeric Antigen Receptor (CAR) enhances directionality of CAR-T cell activity and improves target cell specificity.. 64th American Society of Hematology (ASH) annual Meeting and Exposition 2022.12.10

  2. 松原 淳一, 向井 久美, 近藤 知大, 鹿毛 秀宣, 織田 克利, 工藤 亮, 池田 貞勝, 衣斐 寛倫, 室 圭, 林 龍二, 徳留 なほみ, 山本 信之, 武藤 学. 化学療法未施行切除不能進行がんに対する遺伝子パネル検査の有用性を評価する臨床研究. 日本癌治療学会学術集会抄録集 2022.10.01

  3. Inoue Dai, Ikeda Sadakatsu, Namiki Shin. Molecular profiling of pancreatic cancer and application of liquid biopsy to clinical practice Low detection rate of druggable mutations in CGP using ctDNA in pancreatic cancer(タイトル和訳中). 膵臓 2022.09.01

  4. Mitsukuni Suenaga, Shinichi Yamauchi, Taiki Masuda, Marie Hanaoka, Noriko Iwata, Yuya Sato, Yuya Sato, Chiharu Tomii, Masanori Tokunaga, Yusuke Kinugasa. COVID-19 vaccination in gastrointestinal cancer patients during chemotherapy at a single institute experience. 2022 the Japanese Society Of Medical Oncology Annual Meeting 2022.02.17 Kyoto

  1. 松寺 翔太郎, 加納 嘉人, 岡本 健太郎, 鈴木 完, 小嶋 一幸, 三宅 智, 池田 貞勝. がんゲノム医療推進のためのがんプレシジョンメディシンフェローシッププログラム. 日本癌治療学会学術集会抄録集 2021.10.01

  2. 松寺 翔太郎, 加納 嘉人, 岡本 健太郎, 鈴木 完, 小嶋 一幸, 三宅 智, 池田 貞勝. がんゲノム医療推進のためのがんプレシジョンメディシンフェローシッププログラム. 日本癌治療学会学術集会抄録集 2021.10.01

  3. Satoru Aoyama, Shunichiro Yasuda, Huixin Li, Daisuke Watanabe, Hiroki Akiyama, Keigo Okada, Yoshihiro Umezawa, Ayako Nogami, Osamu Miura, Norihiko Kawamata. Protease mediated Regulatory Chimeric Antigen Receptor (CAR) Improves Target Specificity.. The 83rd Annual Meeting of the Japanese Society of Hematology 2021.09.24

  4. YOSHIHITO KANO, Teklab Gebregiworgis, Christopher Marshall, Mitsuhiko Ikura, Satoshi Miyake, Michael Ohh. KRAS Q61H mutation evades the regulation of tyrosyl phosphorylation and renders cancer cells resistant to SHP2 inhibitor. 第18回日本臨床腫瘍学会学術集会 2021.02.20

  5. 末永光邦、馬島哲夫、若槻尊、清宮啓之. Serum IL-8 level as a candidate prognostic marker of response to anti-angiogenic therapy for metastatic colorectal cancer. 第18 回日本臨床腫瘍学会学術集 2021.02.18 Virtual Congress

  6. 加納嘉人、野地理夏、山下大和、工藤亮、大西威一郎、谷本幸介、宮冬樹、中川剛士、石川敏昭、植竹宏之、絹笠祐介、田邉稔、朝蔭孝宏、原田浩之、岡本隆一、三宅智、池田貞勝. Detection of RAS mutation in solid cancers using NGS-based genome profiling tests. 第18回日本臨床腫瘍学会学術集会 2021.02.18

  7. 加納 嘉人,野地 理夏, 山下 大和, 工藤 亮, 田崎 彰久, 大野 十央, 有泉 陽介, 平井 秀明, 富岡 寛文, 島本 裕彰, 道 泰之, 三浦 雅彦, 吉村 亮一, 朝蔭 孝宏, 原田 浩之, 岡本 隆一, 三宅 智, 池田 貞勝. Clinical utility of tumor-profiling multiplex gene panel testing in advanced head and neck cancer at TMDU. 第18回日本臨床腫瘍学会学術集会 2021.02.18

  1. Satoru Aoyama,Shunichiro Yasuda,Daisuke Watanabe,Hiroki Akiyama,Keigo Okada,Yoshihiro Umezawa,Ayako Nogami,Osamu Miura,Norihiko Kawamata. A Protease-Mediated Regulatory Chimeric Antigen Receptor (CAR): “Double Arm” CAR System Improves Tumor-cell-Specificity of CAR-T Cell Therapy.. 62nd American Society of Hematology (ASH) annual Meeting and Exposition 2020.12.06 virtual meeting

  2. Aoyagi Yasuko, Kano Yoshihito, Ban Daisuke, Tokunaga Masanori, Nakajima Yasuaki, Uetake Hiroyuki, Tanabe Minoru, Miyake Satoshi, Kinugasa Yusuke, Ikeda Sadakatsu. 消化器外科とゲノム医療の将来展望 進行性固形腫瘍患者における包括的ゲノムプロファイリングの臨床的有用性(Future perspectives of cancer genomic medicine in gastroenterological surgery Clinical utility of multiple genomic testing in patients with advanced solid tumor). 日本消化器外科学会総会 2020.12.01

  3. Satoru Aoyama,Shunichiro Yasuda,Daisuke Watanabe,Hiroki Akiyama,Keigo Okada,Yoshihiro Umezawa,Ayako Nogami,Osamu Miura,Norihiko Kawamata. Protease harboring Chimeric Antigen Receptor (CAR) Regulates CAR-T Cell Activity. The 82nd Annual Meeting of the Japanese Society of Hematology 2020.10.10

  4. Yoshihito Kano, Teklab Gebregiworgis, Christopher B. Marshall, Mitsuhiko Ikura, Michael Ohh. Evasion of KRASQ61H regulation by tyrosine phosphorylation renders cancer cells resistant to SHP2 inhibitor. 第79回日本癌学会学術総会 2020.10.01 Hiroshima

  5. 加納 嘉人, Gebregiworgis Teklab, Marshall Christopher, Ikura Mitsuhiko, Ohh Michael. ドライバー遺伝子異常陽性がん治療の新たな局面 KRASQ61H変異によるSHP2阻害剤耐性機構解析. 日本癌学会総会記事 2020.10.01

  6. Satoru Aoyama,Shunichiro Yasuda,Daisuke Watanabe,Hiroki Akiyama,Keigo Okada,Yoshihiro Umezawa,Ayako Nogami,Osamu Miura,Norihiko Kawamata. A Protease-Mediated Regulatory Chimeric Antigen Receptor (CAR): “Scissors” CAR Improves Target Specificity through Regulation of CAR-T Cell Activity. American Association for Cancer Research (AACR) annual meeting 2020 2020.06.22

  7. 上今別府 大作, 若槻 尊, 高張 大亮, 福田 直樹, 佐藤 太龍, 鈴木 健, 大隅 寛木, 中山 厳馬, 末永 光邦, 大木 暁, 小倉 真理子, 篠崎 英司, 山口 研成. 当院でのAFP産生切除不能進行・再発胃癌に対するラムシルマブ併用化学療法の検討(Treatment efficacy of ramucirumab-based chemotherapy in patients with AFP producing gastric cancer). 日本胃癌学会総会記事 2020.03.01

  8. Matsusaka Satoshi, Hanna Diana L., Ning Yan, Yang Dongyun, Cao Shu, Berger Martin D., Miyamoto Yuji, Suenaga Mitsukuni, Dan Shingo, Mashima Tetsuo, Seimiya Hiroyuki, Zhang Wu, Lenz Heinz-Josef. 上皮成長因子受容体のmRNA発現 レゴラフェニブから逃れるための分子機序である可能性(Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib). Cancer Science 2020.02.01

  9. Suenaga, M., Mashima, T., Kawata, N., Wakatsuki, T., Seimiya, H., Yamaguchi, K.. IL-8 levels as candidate marker of antiangiogenic therapy for metastatic colorectal cancer.. ASCO Gastrointestinal Cancers Symposium 2020.01

  10. Suenaga, M., Zhang, W., Mashima, T., Schirripa, M., Cao, S., Okazaki, S., Berger, M. D., Miyamoto, Y., Barzi, A., Lenz, H. J.. Gene polymorphisms of CCL3, CCL4, CCL5, and CCR5 network in metastatic colorectal cancer patients treated with regorafenib. ASCO Gastrointestinal Cancers Symposium 2020.01

  11. Daisaku Kamiimabeppu, Takeru Wakatsuki, Daisuke Takahari, Naoki Fukuda, Hiroki Osumi, Izuma Nakayama, Mariko Ogura, Tarou Sato, Akira Ooki, Eiji Shinozaki, Mitsukuni Suenaga, Keisho Chin, Kensei Yamaguchi. Treatment efficacy of ramucirumab-based chemotherapy in patients with alpha-fetoprotein producing gastric cancer (AFPGC).. ASCO-GI 2020.01

  12. Martin D. Berger, Inti Zlobec, Shu Cao, Yuji Miyamoto, Mitsukuni Suenaga, Shivani Soni, Alberto Puccini, Ryuma Tokunaga, Madiha Naseem, Francesca Battaglin, Wu Zhang, Alessandro Lugli, Heinz-Josef Lenz. Polymorphisms of genes encoding for regulatory proteins in the coagulation cascade to predict outcome for stage II and III colon cancer. ASCO-GI 2020.01

  1. Sadakatsu Ikeda. The clinical significance of comprehensive genomic profiling. ESMO Asia2019 2019.11.22 Singapore, Singapore

  2. Ono Hiroaki, Ikeda Sadakatsu, Ogawa Kosuke, Ogura Toshiro, Ban Daisuke, Kudo Atushi, Miyake Satoshi, Tanaka Shinji, Tanabe Minoru. HBP悪性腫瘍のゲノムシーケンス解析(Genomic sequencing in HBP malignancies). 日本消化器病学会雑誌 2019.11.01

  3. Ono Hiroaki, Ikeda Sadakatsu, Ogawa Kosuke, Ogura Toshiro, Ban Daisuke, Kudo Atushi, Miyake Satoshi, Tanaka Shinji, Tanabe Minoru. HBP悪性腫瘍のゲノムシーケンス解析(Genomic sequencing in HBP malignancies). 日本消化器病学会雑誌 2019.11.01

  4. Ono Hiroaki, Ikeda Sadakatsu, Ogawa Kosuke, Ogura Toshiro, Ban Daisuke, Kudo Atushi, Miyake Satoshi, Tanaka Shinji, Tanabe Minoru. HBP悪性腫瘍のゲノムシーケンス解析(Genomic sequencing in HBP malignancies). 日本消化器病学会雑誌 2019.11.01

  5. Ono Hiroaki, Ikeda Sadakatsu, Ogawa Kosuke, Ogura Toshiro, Ban Daisuke, Kudo Atushi, Miyake Satoshi, Tanaka Shinji, Tanabe Minoru. HBP悪性腫瘍のゲノムシーケンス解析(Genomic sequencing in HBP malignancies). 日本消化器病学会雑誌 2019.11.01

  6. Ono Hiroaki, Ikeda Sadakatsu, Ogawa Kosuke, Ogura Toshiro, Ban Daisuke, Kudo Atushi, Miyake Satoshi, Tanaka Shinji, Tanabe Minoru. HBP悪性腫瘍のゲノムシーケンス解析(Genomic sequencing in HBP malignancies). 日本消化器病学会雑誌 2019.11.01

  7. Satoru Aoyama, Shunichiro Yasuda, Daisuke Watanabe, Yoshihiro Umezawa, Osamu Miura, Norihiko Kawamata. A multi-antigen recognition system for CAR-T technology using a protein cleavage method.. The 81st Annual Meeting of the Japanese Society of Hematology 2019.10.12 Tokyo, Japan

  8. 齋藤 亜由美, 池田 貞勝, 福田 美佐緒, 安次嶺 宏哉, 宮地 康僚, 池 成基, 大山 優. 当院におけるがんゲノム医療の診療経験. 日本癌治療学会学術集会抄録集 2019.10.01

  9. 大島 乃里子, 高橋 健太, 中村 玲子, 吉野 育典, 若菜 公雄, 池田 貞勝, 宮坂 尚幸. 当院における婦人科腫瘍のがんゲノム医療. 日本癌治療学会学術集会抄録集 2019.10.01

  10. 高橋 健太, 熊木 裕一, 横堀 潤子, 高嶺 恵里子, 大島 乃里子, 若菜 公雄, 石川 敏昭, 伴 大輔, 工藤 篤, 木村 浩一朗, 中川 剛士, 田邉 稔, 宮坂 尚幸, 三宅 智, 池田 貞勝. がんの診断・治療とLiquid Biopsyの意義 がんゲノム医療におけるLiquid biopsyの可能性 前向き観察研究PROFILE試験の結果から. 日本癌治療学会学術集会抄録集 2019.10.01

  11. 武藤 学, 金井 雅史, 鶴山 竜昭, 松本 繁巳, 豊岡 伸一, 秋田 弘俊, 松原 久裕, 西原 広史, 末岡 榮三朗, 池田 貞勝. バイオバンキングが切り拓く新しいがん研究 わが国におけるクリニカルバイオバンクネットワークの構築(Innovative cancer research based on biobanking Clinical biobank network in Japan). 日本癌学会総会記事 2019.09.01

  12. 武藤 学, 金井 雅史, 鶴山 竜昭, 松本 繁巳, 豊岡 伸一, 秋田 弘俊, 松原 久裕, 西原 広史, 末岡 榮三朗, 池田 貞勝. バイオバンキングが切り拓く新しいがん研究 わが国におけるクリニカルバイオバンクネットワークの構築(Innovative cancer research based on biobanking Clinical biobank network in Japan). 日本癌学会総会記事 2019.09.01

  13. 武藤 学, 金井 雅史, 鶴山 竜昭, 松本 繁巳, 豊岡 伸一, 秋田 弘俊, 松原 久裕, 西原 広史, 末岡 榮三朗, 池田 貞勝. バイオバンキングが切り拓く新しいがん研究 わが国におけるクリニカルバイオバンクネットワークの構築(Innovative cancer research based on biobanking Clinical biobank network in Japan). 日本癌学会総会記事 2019.09.01

  14. 加納 嘉人, Gebregiworgis Teklab, Marshall Christopher, Ikura Mitsuhiko, Ohh Michael. チロシンリン酸化モデルに基づくKRAS変異膵癌に対する治療戦略(Inhibition of SHP2 promotes the tyrosyl phosphorylation of KRAS and suppresses the pancreatic cancer growth). 日本癌学会総会記事 2019.09.01

  15. 武藤 学, 金井 雅史, 鶴山 竜昭, 松本 繁巳, 豊岡 伸一, 秋田 弘俊, 松原 久裕, 西原 広史, 末岡 榮三朗, 池田 貞勝. バイオバンキングが切り拓く新しいがん研究 わが国におけるクリニカルバイオバンクネットワークの構築(Innovative cancer research based on biobanking Clinical biobank network in Japan). 日本癌学会総会記事 2019.09.01

  16. 武藤 学, 金井 雅史, 鶴山 竜昭, 松本 繁巳, 豊岡 伸一, 秋田 弘俊, 松原 久裕, 西原 広史, 末岡 榮三朗, 池田 貞勝. バイオバンキングが切り拓く新しいがん研究 わが国におけるクリニカルバイオバンクネットワークの構築(Innovative cancer research based on biobanking Clinical biobank network in Japan). 日本癌学会総会記事 2019.09.01

  17. 池田貞勝、他. Comparison of variant detection power between small and medium size panel in clinical sequencing for Japanese patients. 第17回日本臨床腫瘍学会学術集会 2019.07.19

  18. 加納嘉人,Teklab Gebregiworgis, Christopher Marshall, 伊倉 光彦, Michael Ohh. KRASチロシンリン酸化モデルに基づく膵癌新規分子機構と治療戦略. 第17回日本臨床腫瘍学会学術集会 2019.07.18

  19. 池田貞勝. Novel Treatment Strategies using Liquid Biopsy. 第27回日本乳癌学会学術総会 2019.07.11

  20. Yuichi Kumaki, Sadakatsu Ikeda, Thereasa A. Rich, Jing Zhao, Takayuki Yoshino, Byoung Chul Cho, Nir Peled, Ji-Youn Han, Yukimasa Shiotsu, Aleksandra Franovic, Victoria M. Raymond, Razelle Kurzrock, Richard B. Lanman, Jeeyun Lee, Tony S. K. Mok. Comprehensive genomic profiling of circulating cell-free DNA (cfDNA) distinguishes focal amplification (amp) from aneuploidy among MET amps in diverse advanced cancer types. 2019 ASCO annual meeting 2019.06.01 Chicago, USA

  21. Martin D. Berger, Shu Cao, Inti Zlobec, Yuji Miyamoto, Mitsukuni Suenaga, Diana L. Hanna, Shivani Soni, Alberto Puccini, Ryuma Tokunaga, Madiha Naseem, Francesca Battaglin, Wu Zhang, Alessandro Lugli, Heinz-Josef Lenz. Association of genetic variations within the T-cell costimulatory LIGHT gene with outcome in stage II and III colon cancer.. ASCO annual meeting 2019.06

  22. Satoru Aoyama, Shunichiro Yasuda, Daisuke Watanabe, Yoshihiro Umezawa, Osamu Miura, Norihiko Kawamata. A Multi-antigen Recognition CAR-T Cell System Using Protease Mediated Protein Cleavage.. The 10th JSH International Symposium 2019.05.17 Mie, Japan

  23. Fukuda Naoki, Takahari Daisuke, Suzuki Takeshi, Ota Yumiko, Osumi Hiroki, Nakayama Izuma, Wakatsuki Takeru, Ichimura Takashi, Ogura Mariko, Ooki Akira, Suenaga Mitsukuni, Shinozaki Eiji, Chin Keisho, Yamaguchi Kensei. Ramucirumab+weekly nab-Paclitaxel併用療法で治療された胃癌患者の成績(Real world outcomes of gastric cancer patients treated with ramucirumab plus weekly nab-pactitaxel). 日本胃癌学会総会記事 2019.02.01

  24. Ota Yumiko, Takahari Daisuke, Fukuda Naoki, Osumi Hiroki, Nakayama Izuma, Wakatsuki Takeru, Ichimura Takashi, Ogura Mariko, Suenaga Mitsukuni, Shinozaki Eiji, Chin Keisyo, Yamaguchi Kensei. 進行胃癌に対するnivolumabの効果および予後因子(Outcome and prognostic factors of Nivotumab for advanced gastric cancer in our institution). 日本胃癌学会総会記事 2019.02.01

  25. Suenaga, M., Cao, S., Zhang, W., Matsusaka, S., Okazaki, S., Berger, M. D., Miyamoto, Y., Schirripa, M., Barzi, A., Ueno, M., Lenz, H. J. . Role of enterocyte-specific gene polymorphisms in adjuvant treatment for stage III colorectal cancer.. ASCO Gastrointestinal Cancers Symposium 2019.01

  26. Yukiko Izawa, Takashi Ichimura, Keisho Chin, Eiji Shinozaki, Daisuke Takahari, Mitsukuni Suenaga, Mariko Ogura, Takeru Wakatsuki, Hiroki Osumi, Izuma Nakayama, Shinji Mine, Naoki Hiki, Naoki Ishizuka, Kensei Yamaguchi. Feasibility study of diet counseling (DC) with oral nutritional supplements (ONS) for advanced esophageal and gastric cancer during chemotherapy (CT) or chemoradiotherapy (CRT): First report of ONS compliance from a prospective randomized controlled clinical study (DiCON study).. ASCO-GI 2019.01

  27. Kitagawa Y, Osumi H, Shinozaki E, Ota Y, Nakayama I, Suzuki T, Wakatsuki T, Ichimura T, Ogura M, Ooki A, Takahari D, Suenaga M, Chin K, Yamaguchi K.. Safety and efficacy of amrubicin monotherapy in patients with platinum-refractory metastatic neuroendocrine carcinoma of the gastrointestinal tract: a single cancer center retrospective study.. ASCO-GI 2019.01

  28. Martin D. Berger, Sebastian Stintzing, Volker Heinemann, Shu Cao, Yuji Miyamoto, Mitsukuni Suenaga, Diana L. Hanna, Shivani Soni, Alberto Puccini, Ryuma Tokunaga, Madiha Naseem, Francesca Battaglin, Wu Zhang, Chiara Cremolini, Alfredo Falcone, Fotios Loupakis, Heinz-Josef Lenz. Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE. ASCO Gastrointestinal Cancers Symposium 2019.01

  1. Kumaki Y, Ikeda S, Rich TA, Shiotsu Y, Franovic A, Raymond VM, Kurzrock R, Lanman RB, Lee J, Mok TSK. Circulating cell-free DNA molecular profiling among East Asian patients reveals activating MET alterations are common in diverse advanced cancer types. ESMO Asia 2018 Congress 2018.11.24

  2. M Suenaga, T Wakatsuki, M Ogura, T Ichimura, E Shinozaki, I Nakayama, H Osumi, Y Ota, K Chin, T Mashima, H Seimiya, D Takahari, K Yamaguchi.. A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study.. ESMO congress 2018.10

  3. H. Osumi, E. Shinozaki, H. Zembutsu, Y. Takeda, T. Wakatsuki, T. Ichimura, Y. Ota, I. Nakayama, M. Ogura, M. Suenaga, D. Takahari, K. Chin, A. Saiura, S. Takahashi, T. Noda, K. Yamaguch. Clinical relevance of circulating tumor DNA using amplicon-based deep sequencing panel in colorectal cancer patients with liver metastasis. ESMO congress 2018.10

  4. R. Takahashi, T. Wakatsuki, N. Yamamoto, S. Taguchi, E. Shinozaki, H. Osumi, M. Ogura, T. Ichimura, D. Takahari, M. Suenaga, K. Chin, M. Oguchi, M. Ueno, K. Yamaguchi. p16 and PD-L1 expression in locoregional squamous cell carcinoma of the anal canal: A single center retrospective analysis in Japan. ESMO congress 2018.10

  5. M. Berger, S. Stintzing, V. Heinemann, S. Cao, D. Yang, Y. Miyamoto, M. Suenaga, D.L. Hanna, S. Soni, A. Puccini, R. Tokunaga, M. Naseem, F. Battaglin, M. McSkane, W. Zhang, H.-J. Lenz. Genetic variations within the HER3 gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab or FOLFIRI/cetuximab: Data from FIRE-3. ESMO congress 2018.10

  6. Osumi Hiroki, Shinozaki Eiji, Mashima Tetsuo, Wakatsuki Takeru, Suenaga Mitsukuni, Ichimura Takashi, Ogura Mariko, Ota Yumiko, Nakayama Izuma, Takahari Daisuke, Chin Keisho, Miki Yoshio, Yamaguchi Kensei. 既治療のKRASエクソン2野生型大腸癌に対するサードライン療法としてのセツキシマブとイリノテカンの隔週治療の第II相試験(Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer). Cancer Science 2018.08.01

  7. Yoshihito Kano, Teklab Gebregiworgis, Christopher B. Marshall, Nikolina Radulovich, Betty P.K. Poon, Zhong-Yin Zhang, Ming-Sound Tsao, Mitsuhiko Ikura and Michael Ohh. TYROSYL PHOSPHORYLATION OF KRAS DISRUPTS THE GTPASE CYCLE AND INHIBITS PANCREATIC CANCER CELL GROWTH.. DDW2018 2018.06.05

  8. Suenaga, M., Schirripa, M., Loupakis, F., Cao, S., Zhang, W., Cremolini, C., Lonardi, S., Okazaki, S., Berger, M. D., Miyamoto, Y., Soni, S., Barzi, A., Yamaguchi, T., Falcone, A., Lenz, H. J.. Clinical significance of enterocyte-specific gene polymorphisms as candidate marker of oxaliplatin-based treatment for metastatic colorectal cancer.. 54th ASCO annual meeting 2018.06

  9. Teklab Gebregiworgis, Christopher B. Marshall, Yoshihito Kano, Nikolina Radulovich, Ming-Sound Tsao, Michael Ohh, Mitsuhiko Ikura. Altering the regulation of KRAS GTPase cycle via Src and SHP2 creates a potential therapeutic vulnerability for pancreatic cancer. . AACR 2018 2018.04.17

  10. Kano Y. Tyrosyl phosphorylation of KRAS disrupts the GTPase cycle and inhibits pancreatic cancer cell growth. Pizza Talk of Department of Biochemistry 2018.03.21 Toronto(Canada)

  11. 福田 直樹, 高張 大亮, 太田 弓子, 大隅 寛木, 中山 厳馬, 若槻 尊, 市村 崇, 小倉 真理子, 末永 光邦, 篠崎 英司, 陳 勁松, 山口 研成. 胃癌・肝転移のラムシルマブによる画像上形態学的変化の頻度・臨床的意義に関する検討(Morphologic change in gastric cancer patients with liver metastasis treated with ramucirumab). 日本胃癌学会総会記事 2018.03.01

  12. Suenaga, M., Mashima, T., Kawata, N., Dan, S., Wakatsuki, T., Shinozaki, E., Ichimura, T., Ogura, M., takahari, D., Osumi, H., Ota, Y., Chin, K., Seimiya, H., Yamaguchi, K., Yamaguchi, T.. Identification of biomarkers for TAS-102 efficacy in metastatic colorectal cancer patients based on preclinical analysis and clinical validation.. ASCO Gastrointestinal Cancers Symposium 2018.01

  13. Suenaga, M., Schirripa, M., Cao, S., Zhang, W., Yang, D., Cremolini, C., Murgioni, S., Lonardi, S., Ning, Y., Okazaki, S., Berger, M. D., Miyamoto, Y., Gopez, R., Barzi, A., Loupakis, F., Falcone, A., Lenz, H.. Single nucleotide polymorphisms in miRNA binding sites of nucleotide excision repair-related genes predict clinical benefit of oxaliplatin in FOLFOXIRI plus bevacizumab in TRIBE trial.. ASCO Gastrointestinal Cancers Symposium 2018.01

  14. Suenaga, M., Schirripa, M., Cao, S., Zhang, W., Yang, D., Ning, Y., Bergamo, F., Zagonel, V., Rossini, D., Borelli, B., Okazaki, S., Berger, M., Miyamoto, Y., Gopez, R., Barzi, A., Yamaguchi, T., Loupakis, F., Lenz, H. J.. Matrix metalloproteinase-related gene polymorphisms predict efficacy of regorafenib in patients with metastatic colorectal cancer.. ASCO Gastrointestinal Cancers Symposium 2018.01

  15. Yuta Ushida, Eiji Shinozaki, Keisho Chin, Mitsukuni Suenaga, Daisuke Takahari, Masato Ozaka, Mariko Ogura, Takashi Ichimura, Takeru Wakatsuki, TOMOHIRO MATSUSHIMA, Hiroki Osumi, Yumiko Ota, Kensei Yamaguchi. Clinical outcomes of anti-EGFR antibody treatment for right-sided colon cancer patients without RAS, BRAF, and PIK3CA mutations in the later line.. ASCO-GI 2018.01

  16. Ryo Takahashi, Takeru Wakatsuki, Eiji Shinozaki, Senzo Taguchi, Yoshiya Fujimoto, Hiroki Osumi, Yumiko Ota, TOMOHIRO MATSUSHIMA, Mariko Ogura, Takashi Ichimura, Daisuke Takahari, Mitsukuni Suenaga, Keisho Chin, Masahiko Oguchi, Masashi Ueno, Kensei Yamaguchi. Chemoradiation for the treatment of locoregional squamous cell carcinoma of the anal canal: A single center retrospective analysis in Japan.. ASCO-GI 2018.01

  17. Daisuke Takahari, Takeru Wakatsuki, Tetsuo Mashima, Keisho Chin, Takashi Ichimura, Mariko Ogura, TOMOHIRO MATSUSHIMA, Hiroki Osumi, Izuma Nakayama, Yumiko Ota, Eiji Shinozaki, Mitsukuni Suenaga, Naomi Kawata, Yuki Horiike, Hiroyuki Seimiya, Naoya Fujita, Kensei Yamaguchi. Plasma biomarker analysis of ramucirumab in Japanese patients with advanced gastric cancer.. ASCO-GI 2018.01

  18. Yumiko Ota, Takeru Wakatsuki, Tetsuo Mashima, Daisuke Takahari, Keisho Chin, Takashi Ichimura, Mariko Ogura, TOMOHIRO MATSUSHIMA, Hiroki Osumi, Izuma Nakayama, Eiji Shinozaki, Mitsukuni Suenaga, Naomi Kawata, Yuki Horiike, Hiroyuki Seimiya, Naoya Fujita, Kensei Yamaguchi. Plasma biomarker dynamics following ramucirumab treatment and survival analysis after ramucirumab treatment failure in patients with advanced gastric cancer.. ASCO-GI 2018.01

  19. Shusuke Yagi, Eiji Shinozaki, Keisho Chin, Mitsukuni Suenaga, Daisuke Takahari, Mariko Ogura, Takashi Ichimura, Takeru Wakatsuki, Masato Ozaka, Izuma Nakayama, TOMOHIRO MATSUSHIMA, Hiroki Osumi, Kensei Yamaguch. Clinical impact of diverting ileostomy on the dose intensity of adjuvant chemotherapy for colorectal cancer.. ASCO-GI 2018.01

  20. Tomoyuki Nagaoka, Eiji Shinozaki, Ryosuke Watanabe, Eiko Ueno, Yumiko Ota, Hiroki Osumi, Izuma Nakayama, Takeru Wakatsuki, Mariko Ogura, Mitsukuni Suenaga, Takashi Ichimura, Daisuke Takahari, Keisho Chin, Kensei Yamaguchi. Clinical significance of morphologic response and tumor shrinkage as predictive factors of Capeox+bevacizumab in 1st line treatment of metastatic colorectal cancer.. ASCO-GI 2018.01

  21. Tomoyo Oguri, Daisuke Takahari, Yumiko Ota, Hiroki Osumi, Izuma Nakayama, Takeru Wakatsuki, Mariko Ogura, Takashi Ichimura, Mitsukuni Suenaga, Eiji Shinozaki, Keisho Chin, Kensei Yamaguchi. The clinical analysis of thromboembolism in esophagogastric cancer in Japan: A single institute experience.. ASCO-GI 2018.01

  1. Kano Y, Gebregiworgis T, Marshall CB, Radulovich N, Poon B P.K. , Zhang Z, Tsao M, Ikura M, Ohh M. Tyrosyl phosphorylation of KRAS disrupts the GTPase cycle and inhibits pancreatic cancer cell growth. . The Terry Fox Research Institute Ontario Node Research Symposium 2017.12.04 Toronto(Canada)

  2. Nakayama Izuma, Chin Keisho, Matsushima Tomohiro, Takahari Daisuke, Ogura Mariko, Shinozaki Eiji, Suenaga Mitsukuni, Ozaka Masato, Wakatsuki Takeru, Ichimura Takashi, Osumi Hiroki, Yamaguchi Kensei. 腹腔細胞診陽性で肉眼的所見では腹膜転移を認めない進行性胃癌患者の治療に対するS-1+シスプラチンとS-1単剤療法の後向きによる比較検討(Retrospective comparison of S-1 plus cisplatin versus S-1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis). International Journal of Clinical Oncology 2017.12.01

  3. Kano Y, Poon P.K. B, Radulovich N, Zhang Z, Tsao M, Ohh M. Novel treatment strategy for pancreatic cancer by targeting SHP2-mediated dephosphorylation of KRAS oncoprotein. The 4th Canadian Cancer Research Conference 2017.11.06 Vancouver(Canada)

  4. 小口 正彦, 室伏 景子, 田口 千藏, 吉岡 靖生, 角 美奈子, 上野 雅資, 福長 洋介, 長山 聡, 秋吉 高志, 小西 毅, 藤本 佳也, 山口 研成, 篠崎 英司, 末永 光邦, 松阪 諭. 「それぞれの癌」診断・治療の現状と展望 直腸癌 局所進行直腸癌に対する化学放射線療法. 日本癌治療学会学術集会抄録集 2017.10.01

  5. Suenaga, M., Cao, S., Stintzing, S., Zhang, W., Yang, D., Ning, Y., Okazaki, S., Berger, M., Miyamoto, Y., Schirripa, M., Gopez, R., Melendez, E., Soni, S., Barzi, A., Yamaguchi, T., Heinemann, V., Lenz, H.. Genetic polymorphisms of CCL5 and CCR5 to predict efficacy of cetuximab-based treatment in metastatic colorectal cancer patients depending on primary tumor location.. 53rd ASCO annual meeting 2017.06

  6. Suenaga, M., Cao, S., Zhang, W., Ning, Y., Okazaki, S., Berger, M., Miyamoto, Y., Schirripa, M., Gopez, R., Melendez, E., Soni, S., Barzi, A., Yamaguchi, T., Lenz, H. . Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels to predict efficacy of bevacizumab in metastatic colorectal cancer patients receiving first-line chemotherapy.. 53rd ASCO annual meeting 2017.06

  7. Martin D. Berger, Sebastian Stintzing, Dongyun Yang, Shu Cao, Yuji Miyamoto, Mitsukuni Suenaga, Shivani Soni, Roel Gopez, Elizabeth Melendez, Wu Zhang, Volker Heinemann, and Heinz-Josef Lenz. Genetic variations within the vitamin C transporter genes to predict outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial. ASCO Annual Meeting 2017.06

  8. Yuji Miyamoto, Fotios Loupakis, Wu Zhang, Shu Cao, Satoshi Okazaki, Martin D. Berger, Mitsukuni Suenaga, Marta Schirripa, Shivani Soni, Satoshi Matsusaka, Yan Ning, Dongyun Yang, Roel Gopez, Elizabeth Melendez, Diana L. Hanna, Afsaneh Barzi, Hideo Baba, Alfredo Falcone, and Heinz-Josef Lenz. Genetic variations in semaphorin/neuropilin signaling to predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab-based chemotherapy. ASCO Annual Meeting 2017.06

  9. Yuji Miyamoto, Sebastian Stintzing, Volker Heinemann, Wu Zhang, Shu Cao, Satoshi Okazaki, Martin D. Berger, Mitsukuni Suenaga, Marta Schirripa, Shivani Soni, Satoshi Matsusaka, Yan Ning, Dongyun Yang, Roel Gopez, Elizabeth Melendez, Diana L. Hanna, Afsaneh Barzi, Hideo Baba, and Heinz-Josef Lenz. Association of genetic variations in genes implicated in the axis with outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus chemotherapy. ASCO annual meeting 2017.06

  10. Kano Y. Poster Judge. 20th Annual LMP Graduate Research Conference 2017.04.13 Toronto(Canada)

  11. Suenaga, M., Schirripa, M., Cao, S., Zhang, W., Yang, D., Marmorino, F., Bergamo, F., Antoniotti, C., Rossini, D., Ning, Y., Okazaki, S., Berger, M., Miyamoto, Y., Gopez, R., Hanna, D., Barzi, A., Mashima, T., Yamaguchi, T., Loupakis, F., Lenz , H.. Role of genetic polymorphisms in CCL5/CCR5 axis to predict efficacy of regorafenib in patients with refractory metastatic colorectal cancer.. ASCO Gastrointestinal Cancers Symposium 2017.01

  12. Suenaga, M., Schirripa, M., Cao, S., Zhang, W., Yang, D., Salvatore, L., Lonardi, S., Moretto, R., Borelli, B., Ning, Y., Okazaki, S., Berger, M., Miyamoto, Y., Gopez, R., Hanna, D., Barz, A., Wakatsuki, T., Yamaguchi, T., Loupakis, F., Lenz, H.. Lenz, H. Genetic variants of genes in CCL5/CCR5 pathway to predict regorafenib-induced hand-foot skin reaction in patients with refractory metastatic colorectal cancer: A report of ethnic difference.. ASCO Gastrointestinal Cancers Symposium 2017.01

  13. Yuji Miyamoto, Sebastian Stintzing, Wu Zhang, Shu Cao, Yan Ning, Satoshi Okazaki, Martin D. Berger, Mitsukuni Suenaga, Marta Schirripa, Shivani Soni, Satoshi Matsusaka, Dongyun Yang, Roel Gopez, Diana L. Hanna, Afsaneh Barzi, Hideo Baba, Volker Heinemann, Heinz-Josef Lenz. Polymorphisms in adipokine-related genes to predict treatment outcomes in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab-based chemotherapy.. ASCO Gastrointestinal Cancers Symposium 2017.01

  14. Martin D. Berger, Sebastian Stintzing, Volker Heinemann, Dongyun Yang, Shu Cao, Yan Ning, Satoshi Okazaki, Yuji Miyamoto, Mitsukuni Suenaga, Marta Schirripa, Roel Gopez, Diana L. Hanna, Wu Zhang, Heinz-Josef Lenz. Effect of JAK2 SNP rs2274472 on outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial. ASCO Gastrointestinal Cancers Symposium 2017.01

  15. Martin D. Berger, Sebastian Stintzing, Dongyun Yang, Mitsukuni Suenaga, Yuji Miyamoto, Shu Cao, Shivani Soni, Roel Gopez, Diana L. Hanna, Wu Zhang, Volker Heinemann, Heinz-Josef Lenz. Effect of polymorphisms of genes encoding regulatory proteins in the coagulation cascade on outcome for mCRC patients treated with FOLFIRI and bevacizumab: Data from FIRE-3 trial. ASCO Gastrointestinal Cancers Symposium 2017.01

  1. S. Okazaki, F. Loupakis, M. Schirripa, S. Cao, W. Zhang, D. Yang, Y. Ning, M. Berger, Y. Miyamoto, M. Suenaga, R. Gopez, B.B. Borelli, C. Cremolini, A. Falcone, S. Lonardi, L.Salvatore, H. Uetake, T. Kawano, T. Helentjaris, H.-J. Lenz. Tandem repeat variation in HIC1 gene predicts outcome for oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. ESMO congress 2016.10

  2. Suenaga, M., Schirripa, M., Cao, S., Zhang, W., Yang, D., Berger, M., West, J., Cremolin, C., Lonardi, S., Battaglin, F., Ning, Y., Horiike, Y., Yamamoto, N., Okazaki, S., Miyamoto, Y., Hanna, D., Barzi, A., Loupakis, F., Falcone, A., Lenz, H.. Genetic variants of Pin1 to predict benefit from irinotecan and oxaliplatin based treatment in patients with metastatic colorectal cancer (mCRC).. ASCO Annual Meeting. 2016.06

  3. Suenaga, M., Schirripa, M., Cao, S., Zhang, W., Yang, D., Berger, M., West, J., Ning, Y., Salvatore, L., Rossini, D., Antoniotti, C., Inoue, R., Matsusaka, S., Okazaki, S., Miyamoto, Y., Hanna, D., Barzi, A., Loupakis, F., Lenz, H.. Genetic variants of ATM and XRCC3 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.. ASCO annual meeting 2016.06

  4. Yuji Miyamoto, Sebastian Stintzing, Fotios Loupakis, Wu Zhang, Shu Cao, Yan Ning, Satoshi Okazaki, Martin D. Berger, Mitsukuni Suenaga, Marta Schirripa, Satoshi Matsusaka, Dongyun Yang, Jordan David West, Roel Gopez, Diana L. Hanna, Afsaneh Barzi, Hideo Baba, Volker Heinemann, Heinz-Josef Lenz. Genetic variations associated with cancer cachexia pathways to predict survival in metastatic colorectal cancer (mCRC): Results from FIRE-3 and TRIBE. ASCO Annual Meeting 2016.06

  5. Jordan David West, Wu Zhang, Sebastian Stintzing, Yu Sunakawa, Dongyun Yang, Shu Cao, Yan Ning, Martin D. Berger, Roel Gopez, Yuji Miyamoto, Satoshi Okazaki, Mitsukuni Suenaga, Marta Schirripa, Afsaneh Barzi, Diana L. Hanna, Akihito Tsuji, Wataru Ichikawa, Volker Heinemann, Heinz-Josef Lenz. Genetic variants in immune response genes to predict clinical outcome in mCRC patients treated with FOLFIRI/cetuximab (FIRE-3) or with first line cetuximab-based chemotherapy (JACCRO CC-05/06 AR). ASCO Annual Meeting 2016.06

  6. Satoshi Matsusaka, Yan Ning, Dongyun Yang, Wu Zhang, Diana L. Hanna, Shu Cao, Mitsukuni Suenaga, Satoshi Okazaki, Martin D. Berger, Heinz-Josef Lenz. Epidermal growth factor receptor mRNA expression in circulating tumor cells as a potential mechanism of molecular escape from regorafenib therapy. 2016.06

  7. Martin D. Berger ,Sebastian Stintzing, Volker Heinemann, Dongyun Yang, Yu Sunakawa, Yan Ning, Satoshi Matsusaka, Satoshi Okazaki, Yuji Miyamoto, Mitsukuni Suenaga, Marta Schirripa, Jordan David West, Diana L. Hanna, Afsaneh Barzi, Wu Zhang, Heinz-Josef Lenz. MKNK1 SNP rs8602 to predict outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial. ASCO Annual Meeting 2016.06

  8. Marta Schirripa, Wu Zhang, Dongyun Yang, Shu Cao, Satoshi Okazaki, Fotios Loupakis, Martin D. Berger, Yan Ning, Afsaneh Barzi, Yuji Miyamoto, Mitsukuni Suenaga, Roel Gopez, Jordan David West, Diana L. Hanna, Sara Lonardi, Francesca Bergamo, Chiara Cremolini, Alfredo Falcone, Heinz-Josef Lenz. NOS2 polymorphisms in the prediction of benefit from FOLFIRI plus bevacizumab in mCRC patients enrolled in TRIBE trial. ASCO Annual Meeting 2016.06

  9. Roel Gopez, Marta Schirripa, Wu Zhang, Shu Cao, Satoshi Okazaki, Dongyun Yang, Fotios Loupakis, Martin D. Berger, Yan Ning, Yuji Miyamoto, Mitsukuni Suenaga, Jordan David West, Diana L. Hanna, Afsaneh Barzi, Alfredo Falcone, Sebastian Stintzing, Volker Heinemann, Heinz-Josef Lenz. IRS1 and IRS2 polymorphisms and outcome in mCRC patients enrolled in the FIRE-3 trial.. ASCO Annual Meeting 2016.06

  10. Shu Cao, Dongyun Yang, Sebastian Stintzing, Fotios Loupakis, Wu Zhang, Yan Ning, Marta Schirripa, Mitsukuni Suenaga, Satoshi Okazaki, Yuji Miyamoto, Afsaneh Barzi, Heinz-Josef Lenz. Identifying predictive SNPs in patients with metastatic colorectal cancer (mCRC) using Random Survival Forests. ASCO Annual Meeting 2016.06

  11. Marta Schirripa, Dongyun Yang, Fotios Loupakis, Carlotta Antoniotti, Chiara Cremolini, Shu Cao, Satoshi Okazaki, Martin D. Berger, Yan Ning, Yuji Miyamoto, Mitsukuni Suenaga, Roberto Moretto, Francesca Bergamo, Francesca Battaglin, Sara Lonardi, Roel Gopez, Jordan David West, Wu Zhang, Alfredo Falcone, Heinz-Josef Lenz. Females versus males: Clinical features and outcome differences in large molecularly selected cohort of mCRC patients. ASCO Annual Meeting 2016.06

  12. Wu Zhang, Mitsukuni Suenaga, Marta Schirripa, Shu Cao, Dongyun Yang, Martin D. Berger, Jordan David West, Yan Ning, Takeru Wakatsuki, Tetsuo Mashima, Satoshi Okazaki, Yuji Miyamoto, Diana L. Hanna, Federica Marmorino, Lisa Salvatore, Roberto Moretto, Beatrice Borelli, Afsaneh Barzi, Fotios Loupakis, Heinz-Josef Lenz. Genetic variants of hENT-1 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. ASCO Annual Meeting 2016.06

  13. Martin D. Berger, Sebastian Stintzing, Volker Heinemann, Dongyun Yang, Yu Sunakawa, Yan Ning, Satoshi Matsusaka, Satoshi Okazaki, Yuji Miyamoto, Mitsukuni Suenaga, Marta Schirripa, Jordan David West, Afsaneh Barzi, Diana L. Hanna, Wu Zhang, Heinz-Josef Lenz. Polymorphisms of genes encoding for vitamin D binding protein and Wnt5a to predict outcome for mCRC patients treated with first-line FOLFIRI and bevacizumab: Data from FIRE-3 trial. ASCO Annual Meeting 2016.06

  14. Yan Ning, Sebastian Stintzing, Wu Zhang, Dongyun Yang, Diana L. Hanna, Satoshi Okazaki, Martin D. Berger, Yuji Miyamoto, Jordan David West, Mitsukuni Suenaga, Marta Schirripa, Afsaneh Barzi, Volker Heinemann, Heinz-Josef Lenz. Genetic variants of R-spondin genes to predict clinical outcome in mCRC patients (pts) treated with first line FOLFIRI and bevacizumab (FOLFIRI/BEV) in FIRE-3 cohort. ASCO Annual Meeting 2016.06

  15. Satoshi Okazaki, Sebastian Stintzing, Yu Sunakawa, Shu Cao, Wu Zhang, Dongyun Yang, Yan Ning, Martin D. Berger, Jordan David West, Roel Gopez, Yuji Miyamoto, Mitsukuni Suenaga, Marta Schirripa, Afsaneh Barzi, Diana L. Hanna, Akihito Tsuji, Wataru Ichikawa, Volker Heinemann, William DePaolo, Heinz-Josef Lenz. Polymorphisms in toll-like receptor (TLR) genes in the prediction of outcome for cetuximab-based treatment in patients with metastatic colorectal cancer (mCRC). ASCO Annual Meeting 2016.06

  16. Osumi Hiroki, Yoshio Toshiyuki, Chin Keisho, Ogura Mariko, Kumekawa Yosuke, Suenaga Mitsukuni, Matsusaka Satoshi, Shinozaki Eiji, Miyamoto Yuji, Morishige Kenjiro, Ishiyama Akiyoshi, Hirasawa Toshiaki, Tsuchida Tomohiro, Yamamoto Yorimasa, Fujisaki Junko, Igarashi Masahiro, Mizunuma Nobuyuki. 化学療法は同時性重複食道癌患者における胃癌第1期に有効である(Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer). Gastric Cancer 2016.04.01

  17. 陳 勁松, 小倉 真理子, 市村 崇, 高張 大亮, 篠崎 英司, 尾阪 将人, 松阪 諭, 末永 光邦, 水沼 信之. 高齢者胃癌の治療戦略 80歳以上の転移進行胃癌患者への化学療法は有用か?(Systemic chemotherapy for 80 years or over patients with advanced gastric cancer). 日本胃癌学会総会記事 2016.03.01

  18. Tsuyoshi Konishi, Eiji Shinozaki, Keiko Murofushi, Masashi Ueno, Yosuke Fukunaga, Satoshi Nagayama, Yoshiya Fujimoto, Takashi Akiyoshi, Mitsukuni Suenaga, Satoshi Matsusaka, Akiko Chino, Hiroshi Kawachi, Noriko Yamamoto, Yuichi Ishikawa, Masahiro Igarashi, Masahiko Oguchi, Nobuyuki Mizunuma, Takeshi Sano, Toshiharu Yamaguchi. Phase II trial of induction mFOLFOX6 plus bevacizumab followed by neoadjuvant S-1-based chemoradiation for MRI-defined poor-risk rectal cancer.. ASCO-GI 2016.01

  19. Satoshi Okazaki, Sebastian Stintzing, Volker Heinemann, Shu Cao, Wu Zhang, Dongyun Yang, Yan Ning, Satoshi Matsusaka, Martin D. Berger, Jordan D. West, Yuji Miyamoto, Mitsukuni Suenaga, Heinz-Josef Lenz. Association of TLR9 polymorphism with overall survival in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab enrolled in FIRE3.. ASCO-GI 2016.01

  20. Martin D. Berger, Sebastian Stintzing, Volker Heinemann, Dongyun Yang, Yu Sunakawa, Yan Ning, Satoshi Matsusaka, Satoshi Okazaki, Yuji Miyamoto, Mitsukuni Suenaga, Jordan David West, Wu Zhang, Nicos Petasis, Heinz-Josef Lenz. Serum amyloid α (SAA-1) SNP rs12218 to predict outcome for mCRC patients treated with FOLFIRI and bevacizumab: Data from FIRE-3 trial.. ASCO-GI 2016.01 SF, US

  1. 8. Keita Fukushima, Kiichiro Tsuchiya, Shuji Hibiya, Ryohei Hayashi, Nobukatsu Horita, Yoshihito Kano, Ryuichi Okamoto, Tetsuya Nakamura, Mamoru Watanabe.. Atoh1 Protein Expression by TNF-a and the Acquisition of Malignant Potential in Colitis- Associated Colorectal Cancer. . DDW 2015 2015.05.17

  2. 9. Shuji Hibiya, Kiichiro Tsuchiya, Keita Fukushima, Ryohei Hayashi, Nobukatsu Horita, Yoshihito Kano, Ryuichi Okamoto, Tetsuya Nakamura,Mamoru Watanabe. Continuous stimulation with cytokines leads to irreversible accumulation of NF-κB signaling in colonic epithelial cells.. The 5th International Symposium on Carcinogenic Spiral 2015.02.26

  3. M. Suenaga, N. Mizunuma, S. Matsusaka, E. Shinozaki, M. Ozaka, M. Ogura, K. Chin, T. Yamaguchi.. A phase II study of Oxaliplatin Reintroduction in patients pretreated with Oxaliplatin and Irinotecan for Advanced Colorectal Cancer (RE-OPEN study).. ASCO Gastrointestinal Cancers Symposium 2015.01

  1. Mitsukuni Suenaga, Nobuyuki Mizunuma, Satoshi Matsusaka, Eiji Shinozaki, Masato Ozaka, Mariko Ogura, Keisho Chin, Toshiharu Yamaguchi. A Phase I/II study of Bi-weekly XELIRI with capecitabine 1,000 mg/m2 twice daily and irinotecan 180 mg/m2 plus bevacizumab (BV) for patient with Metastatic Colorectal Cancer as second-line chemotherapy . ESMO annual congress 2014.09.29 Madrid

  2. 11. Horita N, Tsuchiya K, Hayashi R, Fukushima K, Hibiya S, Fukuda M, Kano Y, Mizutani T, Nemoto Y, Yui S, Okamoto R, Nakamura T, Watanabe M. Establishment of the gene transduction into the primary intestinal organoid identified the subpopulation of the stem cells in a crypt.. 第12回幹細胞シンポジウム 2014.05.31

  3. 12. Hibiya S, Tsuchiya K, Fukushima K, Hayashi R, Horita N, Kano Y, Okamoto R, Nakamura T, Watanabe M.. Long-term stimulation with cytokines acquires irreversible accumulation of NF-κB signaling in primary colonic epithelial cells. . 4th International Symposium on Carcinogenic Spiral 2014.02.11

  4. Takeru Wakatsuki, Keisho Chin, Satoshi Matsusaka, Mariko Ogura, Masato Ozaka, Mitsukuni Suenaga, Eiji Shinozaki, Izuma Nakayama, Nobuyuki Mizunuma. Exploratory analysis to investigate clinical factors that may influence trastsuzumab efficacy in patients with HER2-positive gastric cancer.. ASCO-GI 2014.01 SF, US

  5. Hiroki Osumi, Satoshi Matsusaka, Mitsukuni Suenaga, Takeru Wakatsuki, Mariko Ogura, Masato Ozaka, Eiji Shinozaki, Keisho Chin, Nobuyuki Mizunuma. Quantitative analysis of the impact of deepness of response on survival time following patients with metastatic colorectal cancer treated by chemotherapy and anti-EGFR monoclonal antibodies.. ASCO-GI 2014.01 SF, US

  6. Mitsukuni Suenaga, Satoshi Matsusaka, Eiji Shinozaki, Mariko Ogura, Masato Ozaka, Izuma Nakayama, Takeru Wakatsuki, Keisho Chin, Nobuyuki Mizunuma, Toshiharu Yamaguchi.. SDF-1 and VEGF-C is potential circulating angiogenic biomarkers for bevacizumab in patients with metastatic colorectal cancer.. ASCO Gastrointestinal Cancers Symposium 2014.01

  1. 15. 加納 嘉人, 土屋 輝一郎, 渡辺 守. Atoh1 protein stabilization acquired cancer stem cell phenotype and niche in colon cancer.. 第72回日本癌学会総会 2013.10.03

  2. 加納 嘉人, 土屋 輝一郎, 渡辺 守. Atoh1蛋白安定による癌幹細胞形質獲得とニッチ形成(Atoh1 protein stabilization acquired cancer stem cell phenotype and niche in colon cancer). 日本癌学会総会記事 2013.10.01

  3. 加納 嘉人, 土屋 輝一郎, 渡辺 守. Atoh1蛋白安定による癌幹細胞形質獲得とニッチ形成(Atoh1 protein stabilization acquired cancer stem cell phenotype and niche in colon cancer). 日本癌学会総会記事 2013.10.01

  4. 加納 嘉人, 土屋 輝一郎, 渡辺 守. Atoh1 protein stabilization acquired cancer stem cell phenotype and niche in colon cancer. . GI Research Academy 2013 2013.06.05

  5. Mitsukuni Suenaga, Nobuyuki Mizunuma, Satoshi Matsusaka, Eiji Shinozaki, Masato Ozaka, Mariko Ogura, Keisho Chin, Toshiharu Yamaguchi.. A phase II study of oxaliplatin reintroduction in patients pretreated with oxaliplatin and irinotecan for advanced colorectal cancer (RE-OPEN study): Reports of interim analysis.. ASCO Gastrointestinal Cancers Symposium 2013.01

  1. 加納 嘉人, 土屋 輝一郎, 渡辺 守. Atoh 1蛋白安定による癌幹細胞形質獲得機構解析(The acquirement of cancer stemness in colon cancer by the Atoh1 protein stabilization). 日本癌学会総会記事 2012.08.01

  2. 加納 嘉人, 土屋 輝一郎, 渡辺 守. Atoh 1蛋白安定による癌幹細胞形質獲得機構解析(The acquirement of cancer stemness in colon cancer by the Atoh1 protein stabilization). 日本癌学会総会記事 2012.08.01

  3. 土屋 輝一郎, 加納 嘉人, 渡辺 守. 炎症関連大腸癌におけるAtoh1蛋白安定はがん幹細胞形質と抗がん剤耐性を獲得する(The stabilization of Atoh1 protein in colitic cancer induces cancer stemness and chemoresistance). 日本癌学会総会記事 2012.08.01

  4. 20. 加納 嘉人, 土屋 輝一郎, 渡辺 守.. NEW CLASSIFICATION BASED ON ATOH1 EXPRESSION IN COLON CANCER MIGHT BE USEFUL AS BIOMARKER.. 第10回日本臨床腫瘍学会学術総会 2012.07.26

  5. 21. Kano Y, Tsuchiya K, Zheng X, Horita N, Okamoto R, Nakamura T, Watanabe M.. The acquisition of cancer stemness in colon cancer by the Atoh1 protein stabilization. International Society for Stem Cell Research 2012 2012.06.14

  6. 22. Tsuchiya K, Zheng X, Kano Y, Horita N, Okamoto R, Nakamura T, Watanabe M.. Flagellin Response via TLR5 on Basolateral Membrane of Primary Intestinal Epithelial Cells is Regulated by Notch Signaling. . DDW2012 2012.05.22

  7. 23. Kano Y, Tsuchiya K, Zheng X, Horita N, Okamoto R, Nakamura T, Watanabe M. . The acquisition of cancer stemness in colon cancer by the Atoh1 protein stabilization.. DDW2012 2012.05.19

  8. Itatani Yoshiro, Akiyoshi Takashi, Kuroyanagi Hiroya, Yamakawa Keiko, Noaki Rota, Konishi Tsuyoshi, Fujimoto Yoshiya, Ueno Masashi, Oya Masatoshi, Suenaga Mitsukuni, Yamaguchi Toshiharu. 病初は切除不能であった、骨盤壁に浸潤する局所進行直腸癌に対するFOLFOX4+bevacizumabと術前化学放射線療法施行後の全直腸間膜切除術 症例報告(Total mesorectal excision of initially unresectable locally advanced rectal cancer infiltrating the pelvic wall after treatment with FOLFOX4 plus bevacizumab and preoperative chemoradiation: report of a case). Surgery Today 2012.01.01

  9. Satoshi Matsusaka, Mitsukuni Suenaga, Yuji Mishima, Yasuhito Terui, Eiji Shinozaki, Nobuyuki Mizunuma, Kiyohiko Hatake. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer.. ASCO-GI 2012.01

  10. Dai Inoue, Satoshi Matsusaka, Noriko Yamamoto, Mitsukuni Suenaga, Yuji Mishima, Eiji Shinozaki, Yasuhito Terui, Nobuyuki Mizunuma, Yuichi Ishikawa, Kiyohiko Hatake. CD133 status influences in prognosis of patients with metastatic colorectal cancer receiving cetuximab.. ASCO-GI 2012.01 SF, US

  11. Eiji Shinozaki, Noriko Yamamoto, Keisho Chin, Mariko Ogura, Mitsukuni Suenaga, Satoshi Matsusaka, Nobuyuki Mizunuma, Toshiharu Yamaguchi, Kiyohiko Hatake. How many biopsy fragments will be necessary to assess HER2 status for gastric cancer?. ASCO-GI 2012.01 SF, US

  12. Toshiyasu Watanabe, Eiji Shinozaki, Sho Kijima, Yoshihito Ohhara, Yasutoshi Kuboki, Koichi Takagi, Masato Ozaka, Mariko Ogura, Yoshinori Kikuchi, Mitsukuni Suenaga, Keisho Chin, Satoshi Matsusaka, Junichi Koike, Kimihiko Funahashi, Yoshihisa Urita, Nobuyuki Mizunuma, Kiyohiko Hatake, Hironori Kaneko, Motonobu Sugimoto. Does panitumumab have a clinical benefit in cetuximab-refractory KRAS wild-type metastatic colorectal cancer?. ASCO-GI 2012.01

  13. Yoshihito Ohhara, Mitsukuni Suenaga, Satoshi Matsusaka, Eiji Shinozaki, Nobuyuki Mizunuma, Toshiharu Yamaguchi, Kiyohiko Hatake. Comparison between the three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer.. ASCO-GI 2012.01 SF, US

  14. Yoshihito Ohhara, Keisho Chin, Mariko Ogura, Mitsukuni Suenaga, Eiji Shinozaki, Satoshi Matsusaka, Nobuyuki Mizunuma, Toshiharu Yamaguchi, Kiyohiko Hatake. What are the limiting factors related to discontinuance of chemotherapy after failure of first-line S-1 plus CDDP in Japanese patients with advanced gastric cancer?. ASCO-GI 2012.01 SF, US

  15. Kazuyoshi Kawakami, Mitsukuni Suenaga, Takashi Yokokawa, Kazuo Sugita, Yutaro Mae, Eri Nakamoto, Hiroshi Imada, Nobuyuki Mizunuma, Toshiharu Yamaguchi, Toshihiro Hama. Effect of moisturizers on prevention of hand-foot syndrome associated with capecitabine plus oxaliplatin.. ASCO-GI 2012.01 SF, US

  16. Mitsukuni Suenaga, Satoshi Matsusaka, Nobuyuki Mizunuma, Eiji Shinozaki, Mariko Ogura, Masato Ozaka, Koichi Takagi, Toshiharu Yamaguchi, Kiyohiko Hatake.. Addition of bevacizumab to first-line FOLFOX4 and overall survival in patients with metastatic colorectal cancer.. ASCO Gastrointestinal Cancers Symposium 2012.01

  17. Mitsukuni Suenaga, Satoshi Matsusaka, Eiji Shinozaki, Nobuyuki Mizunuma, Kiyohiko Hatake, Toshiharu Yamaguchi.. A phase I/II study of biweekly XELIRI plus bevacizumab for patients with metastatic colorectal cancer as second-line chemotherapy (BIXER study): Reports of phase I part and interim analysis of phase II part.. ASCO Gastrointestinal Cancers Symposium 2012.01

  1. 26. Kano Y, Tsuchiya K, Zheng X, Horita N, Okamoto R, Nakamura T, Watanabe M. The acquirement of cancer stemness in colon cancer by the Atoh1 protein stabilization.. 1st GDRI France-Japan Cancer Meeting 2011.11.23

  2. 土屋 輝一郎, 加納 嘉人, 渡辺 守. 大腸癌におけるAtoh1蛋白安定は粘液癌の形質を模倣する(The stabilization of Atoh1 protein in colorectal cancer mimics mucinous adenocarcinoma). 日本癌学会総会記事 2011.09.01

  3. 加納 嘉人, 土屋 輝一郎, 渡辺 守. 大腸癌におけるAtoh1蛋白安定発現は分化形質だけでなく癌悪性形質を誘導する(Atoh1 protein stabilization in colorectal cancer promotes not only the differentiation but also the malignancy). 日本癌学会総会記事 2011.09.01

  4. 加納 嘉人, 土屋 輝一郎, 渡辺 守. 大腸癌におけるAtoh1蛋白安定発現は分化形質だけでなく癌悪性形質を誘導する(Atoh1 protein stabilization in colorectal cancer promotes not only the differentiation but also the malignancy). 日本癌学会総会記事 2011.09.01

  5. 土屋 輝一郎, 加納 嘉人, 渡辺 守. 大腸癌におけるAtoh1蛋白安定は粘液癌の形質を模倣する(The stabilization of Atoh1 protein in colorectal cancer mimics mucinous adenocarcinoma). 日本癌学会総会記事 2011.09.01

  6. Yoshitaka HONMA, Masataka TAGURI , Narikazu BOKU, Takahiro TSUSHIMA, Hideaki TAKAHASHI, Shinya UEDA, Tomohiro NISHINA, Hiroki KAWAI, Shunsuke KATO, Mitsukuni SUENAGA. Prognostic Factors of 127 Patients with Advanced Small-bowel Adenocarcinoma Treated with Systemic Chemotherapy. . ECCO annual meeting 2011.09

  7. akahashi Hideaki, Taguri Masataka, Boku Narikazu, Tsushima Takahiro, Honma Yoshitaka, Ueda Shinya, Nishina Tomohiro, Kawai Hiroki, Kato Shunsuke, Kunieda Kenji, Suenaga Mitsukuni, Tamura Fumio, Uchino Keita, Hata Yasuhiro, Horimatsu Takahiro. Prognostic factors of 127 patients with advanced small-bowel adenocarcinoma treated with systemic chemotherapy. 第9回日本臨床腫瘍学会学術集会 2011.07.22 横浜

  8. 大場 大, 陳 勁松, 篠崎 英司, 末永 光邦, 松阪 諭, 水沼 信之, 畠 清彦, 山口 俊晴. Second-line settingでのCPT-11の利用は進行性胃癌の生存率を向上させる(Availability of CPT-11 in second-line setting provides survival benefit for advanced gastric cancer). 日本消化器外科学会総会 2011.07.01

  9. Matsusaka Satoshi, Suenaga Mitsukuni, Mishima Yuji, Kuniyoshi Ryoko, Takagi Koichi, Terui Yasuhito, Mizunuma Nobuyuki, Hatake Kiyohiko. 転移性結腸直腸癌の日本人患者における化学療法に対する反応性を決定するためのサロゲートマーカーとしての循環中腫瘍細胞(Circulating tumor cells as a surrogate marker for determining response to chemotherapy in Japanese patients with metastatic colorectal cancer). Cancer Science 2011.06.01

  10. S. Matsusaka, N. Mizunuma, M. Suenaga, K. Chin, E. Shinozaki, T. Watanabe, Y. Kawazoe, Y. Kuboki, Y. Terui, K. Hatake. Use of circulating endothelial cells to predict response to FOLFOX4 plus bevacizumab in metastatic colorectal cancer.. ASCO Gastrointestinal Cancers Symposium 2011.01.22 SF, US

  11. T. Tsushima, N. Boku, Y. Honma, H. Takahashi, S. Ueda, T. Nishina, H. Kawai, S. Kato, M. Suenaga, F. Tamura. Retrospective analysis of first-line chemotherapy in 132 patients with advanced small-bowel adenocarcinoma.. ASCO Gastrointestinal Cancers Symposium 2011.01.21 SF, US

  12. S. Matsusaka, K. Chin, N. Mizunuma, M. Ogura, M. Suenaga, M. Ozaka, K. Takagi, M. Oba, Y. Mishima, K. Hatake. Use of circulating tumor cells to predict response to chemotherapy in patients with advanced gastric cancer.. ASCO Gastrointestinal Cancers Symposium 2011.01.20 SF, US

  13. M. Suenaga, S. Matsusaka, T. Watanabe, K. Takagi, Y. Kuboki, M. Ozaka, E. Shinozaki, K. Chin, N. Mizunuma, K. Hatake.. Coagulo-fibrinolytic activity as predictor of efficacy in bevacizumab-combined chemotherapy in metastatic colorectal cancer patients.. ASCO Gastrointestinal Cancers Symposium 2011.01

  14. M. Suenaga, H. Imada, E. Nakamoto, S. Matsusaka, T. Watanabe, Y. Kawazoe, E. Shinozaki, K. Chin, N. Mizunuma, K. Hatake.. Optimal use of antihypertensive agents in management of bevacizumab-associated hypertension. . ASCO Gastrointestinal Cancers Symposium 2011.01

  15. M. Suenaga, N. Mizunuma, S. Matsusaka, E. Shinozaki, M. Ogura, Y. Kuboki, T. Watanabe, M. Ozaka, K. Chin, K. Hatake.. Addition of bevacizumab to first-line FOLFOX improves efficacy, including response rate, progression-free survival and overall survival, in patients with metastatic colorectal cancer.. ASCO Gastrointestinal Cancers Symposium 2011.01

  1. 大場 大, 陳 勁松, 小倉 真理子, 久保木 恭利, 河添 悦昌, 渡邊 利泰, 高木 浩一, 尾阪 将人, 篠崎 英司, 末永 光邦, 松阪 諭, 水沼 信之, 畠 清彦. 進行胃癌におけるセカンドライン化学療法としてのイリノテカン 臨床における効果と実用性に関する後向き研究(Irinotecan as 2nd-line chemotherapy in advanced gastric cancer: Retrospective study of efficacy and feasibility in clinical practice). 日本消化器病学会雑誌 2010.09.01

  2. Suenaga Mitsukuni, Ito Yoshinori, Hatake Kiyohiko, Takahashi Shunji, Yokoyama Masahiro, Hashigami Kiyoshi, Onozawa Yusuke, Yamazaki Kentaro, Hironaka Shuichi, Boku Narikazu. 分子標的治療 日本人の進行性固形腫瘍患者におけるneratinib(HKI-272)の安全性、許容性および薬理動態(Molecular target therapy Safety, tolerability, and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors). 日本癌学会総会記事 2010.08.01

  3. 加納 嘉人, 土屋 輝一郎, 渡辺 守. Atoh1蛋白可視化による未分化大腸がん分化誘導機構解析(The induction of the differentiation of colorectal cancer cells indicated by the visualization of Atoh1 protein). 日本癌学会総会記事 2010.08.01

  4. 加納 嘉人, 土屋 輝一郎, 渡辺 守. Atoh1蛋白可視化による未分化大腸がん分化誘導機構解析(The induction of the differentiation of colorectal cancer cells indicated by the visualization of Atoh1 protein). 日本癌学会総会記事 2010.08.01

  5. 朝井洋晶・篠崎英司・水沼信之・渡邊利康・野崎明・久保木恭利・市村崇・高木浩一・尾阪将人・小倉真理子・末永光邦・松阪諭・陳勁松・畠清彦. cetuximab 併用療法での奏効は治療成功期間を延長する〜再発・転移大腸癌72症例の後方視的解析より〜. 第8回日本臨床腫瘍学会 2010.03 東京

  6. 河添悦昌・篠崎英司・細永真理・久保木恭利・市村崇・渡邊利康・大場大・高木浩一・尾阪将人・小倉真理子・末永光邦・松阪諭・陳勁松・水沼信之・畠清彦. FOLFOX療法による脾腫が血小板減少および肝酸素に与える影響. 第8回日本臨床腫瘍学会 2010.03 東京

  7. 松阪諭・三嶋雄二・水沼信之・末永光邦・篠崎英司・陳勁松・小倉真理子・尾阪将人・高木浩一・渡邊利康・野崎明・大場大・河添悦昌・照井康仁・畠清彦. Bevacizumabに対するバイオマーカーはCEPおよび,CXCR4+CEC である. 第8回日本臨床腫瘍学会 2010.03 東京

  8. 渡邊利泰・篠崎英司・朝井洋昌・久保木恭利・大戸雅史・河添悦昌・野崎明・高木浩一・尾阪将人・小倉真理子・末永光邦・松阪諭・陳勁松・水沼信之・畠清彦. 高齢者ではCetuximabのさ瘡洋皮疹が軽くなる可能性がある. 第8回日本臨床腫瘍学会 2010.03 東京

  9. 篠崎英司・水沼信之・朝井洋晶・渡邊利康・野崎明・松阪諭・末永光邦・陳勁松・小倉真理子・尾阪将人・久保木恭利・高木浩一・市村崇・畠清彦. cetuximabの治療を受けた大腸癌患者における血清Mgの早期低下は病勢コントロールと相関する可能性. 第8回日本臨床腫瘍学会 2010.03 東京

  10. 水沼信之・篠崎英司・末永光邦・松阪諭・久保木恭利・野崎明・高木浩一・渡邊利康・河添悦昌・畠清彦. 大腸癌に対する化学療法、癌研有明病院でのレトロスペクテイブ的解析. 第8回日本臨床腫瘍学会 2010.03 東京

  11. 渡邉利泰、末永光邦、久保木泰利、市村崇、川添悦昌、野崎明、大場大、高木浩一、尾阪将人、小倉真理子、篠崎英司、松阪諭、陳頸松、水沼信之、畠清彦. 大腸癌患者におけるBevacizumabの投与規定因子とリスク. 第8回日本臨床腫瘍学会 2010.03 東京

  12. 大場大・陳勁松・久保木恭利・市村崇・河添悦昌・渡邊利泰・服部正也・高木浩一・尾阪将人・小倉真理子・篠崎英司・末永光邦・松阪諭・水沼信之・畠清彦. 進行胃癌2次化学療法におけるirinotecan治療の意義. 第8回日本臨床腫瘍学会 2010.03 東京

  13. 高木浩一・陳勁松・大場大・久保木恭利・大戸雅史・市村崇・河添悦昌・渡邊利泰・尾阪将人・小倉真理子・末永光邦・篠崎英司・松阪諭・水沼信之・畠清彦. S-1耐性胃癌に対するパクリタキセル療法の有効性. 第8回日本臨床腫瘍学会 2010.03 東京

  14. 小倉真理子・松阪諭・久保木恭利・市村崇・渡邊利泰・高木浩一・野崎明・尾阪将人・篠崎英司・末永光邦・陳勁松・水沼信之・畠清彦. 進行再発大腸癌に対するFOLFOX4療法の治療成績. 8回日本臨床腫瘍学会 2010.03 東京

  15. 久保木恭利・篠崎英司・市村崇・尾阪将人・大場大・小倉真理子・末永光邦・松阪諭・陳勁松・水沼信之・畠清彦. 進行再発胃癌患者におけるCDDPの外来投与の規制因子は消化器毒性である. 第8回日本臨床腫瘍学会 2010.03 東京

  16. 陳勁松・吉本和仁・水沼信之・松阪諭・篠崎英司・末永光邦・小倉真理子・尾阪将人・久保木恭利・市村崇・高木浩一・野崎明・渡邊利泰・畠清彦. 胃がん原発巣の化学療法効果判定におけるCTと内視鏡の比較. 第8回日本臨床腫瘍学会 2010.03 東京

  17. 尾阪将人・久保木恭利・市村崇・河添悦晶・渡邊利康・高木浩一・大場大・小倉真理子・篠崎英司・末永光邦・松阪諭・陳勁松・水沼信之・畠清彦. Imatinib投与後、根治療可能なPR症例ではいつ手術を行うべきか?imatinib投与39例の後方視的毛解析より. 第8回日本臨床腫瘍学会 2010.03 東京

  18. 大戸雅史・篠崎英司・久保木恭利・市村崇・渡邊利康・高木浩一・尾阪将人・小倉真理子・末永邦光・松阪諭・陳勁松・水沼信之・畠清彦・山本智理子. 食道癌の根治的化学療法における効果測因子としての血清p53抗体の意義. 第8回日本臨床腫瘍学会 2010.03 東京

  19. K. Yoshimoto, K. Chin, H. Yoshimatsu, T. Ichimura, M. Ozaka, M. Ogura, M. Suenaga, E. Shinozaki, S. Matsuzaka, N. Mizunuma, K. Hatake. Comparison of evaluation with endoscopy and CT for primary lesions of the advanced gastric cancer.. ASCO-GI 2010.01 SF, US

  20. E. Shinozaki, N. Mizunuma, H. Asai, T. Watanabe, A. Nozaki, S. Matsusaka, M. Suenaga, K. Hatake. Correlation of early serum magnesium reduction with disease control in metastatic colorectal cancer treated with cetuximab. ASCO-GI 2010.01 SF, US

  21. S. Matsusaka, N. Mizunuma, M. Suenaga, E. Shinozaki, K. Takagi, K. Chin, Y. Mishima, Y. Terui, K. Hatake. Are circulating tumor cells (CTC) and EGFR status of CTC useful as a surrogate marker for determining response to cetuximab in metastatic colorectal cancer?. ASCO-GI 2010.01 SF, US

  1. 久保木恭利、篠崎英司、尾阪将人、小倉真理子、末永光邦、松阪諭、陳頸松、水沼信之、畠清彦. 進行・再発胃癌に対するS-1/CDDP療法のCDDP外来投与の安全性後方視的解析. 第7回日本臨床腫瘍学会 2009.03 名古屋

  2. 西 陽子、末永 光邦、水沼 信之、篠崎 英司、松阪 諭、陳 勁松、久保木 泰利、野崎 明、尾阪 将人、高木 浩一、渡邊 利泰、植木 信江、小坂 泰二郎、小倉 真理子、畠 清彦. Bevacizumab(Bev)/FOLFIRI併用療法の進行・再発結腸直腸癌に対する安全性と有効性. 第7回日本臨床腫瘍学会 2009.03 名古屋

  3. 野崎明、篠崎英司、、渡邊利泰、高木浩一、西陽子、植木 信江、小坂 泰二郎、尾阪将人、小倉真理子、松阪諭、末永光邦、陳頸松、水沼信之、畠清彦、山本智理子. 結腸・直腸癌における免疫組織化学腺食によるEGFR偽陰性をどう取り扱うか?. 第7回日本臨床腫瘍学会 2009.03 名古屋

  4. 尾阪将人、松阪諭、久保木恭利、渡邊利泰、野崎明、西陽子、高木浩一、小倉真理子、篠崎英司、末永光邦、陳頸松、水沼信之、畠清彦. 実臨床におけるFOLFOX耐性後、2次治療としてのFOLFIRI療法の治療成績. 第7回日本臨床腫瘍学会 2009.03 名古屋

  5. 布施 望、末永 光邦、山口 達郎、松本 寛、水沼 信之、土井 俊彦、畠 清彦、大津 敦 FOLFIRI+BV臨床試験共同研究グループ. 初回治療の進行・再発結腸・直腸癌に対するFOLFIRI+ベバシズマブ(BV)療法の初期安全性及び薬物相互作用の検討. 第7回日本臨床腫瘍学会 2009.03 名古屋

  6. Suenaga Mitsukuni, Mizunuma Nobuyuki, Chin Keisho, Matsusaka Satoshi, Shinozaki Eiji, Oya Masatoshi, Ueno Masashi, Yamaguchi Toshiharu, Muto Tetsuichiro, Konishi Fumio, Hatake Kiyohiko. 単施設での小腸腺癌に対する化学療法(Chemotherapy for Small-Bowel Adenocarcinoma at a Single Institution). Surgery Today 2009.01.01

  7. M. Suenaga, N. Mizunuma, E. Shinozaki, S. Matsusaka, Y. Kuboki, K. Kobayashi, K. Chin, Y. Fujiwara, K. Matsueda, K. Hatake.. Anticoagulant therapy against venous thromboembolism detected by Doppler ultrasound imaging in patients treated with bevacizumab.. ASCO Gastrointestinal Cancers Symposium 2009.01

  1. 小林心、末永光邦、篠崎英司、松阪諭、陳頸松、久保木泰利、市村崇、尾阪将人、小倉真理子、松田正典、藤原良将、松枝清、小野寺久、水沼信之、畠清彦. Bevacizumabを用いた大腸がん化学療法前後に生じた静脈血栓症に対するマネージメント. 第6回日本臨床腫瘍学会 2008.03 福岡

  2. 市村崇、陳頸松、小林心、尾阪将人、久保木泰利、小倉真理子、松田正典、末永光邦、松阪諭、水沼信之、畠清彦. 切除不能・進行胃癌の化学療法中に合併した出血、穿孔、血栓症例. 第6回日本臨床腫瘍学会 2008.03 福岡

  3. 尾阪将人,篠崎英司、小林心、久保木泰利、市村崇、松田正典、小倉真理子、陳頸松、末永光邦、松阪諭、水沼信之、畠清彦. FOLFOX療法によ利Complete Responseが得られた進行・転移性結腸直腸癌の後方視的臨床病理学的解析. 第6回日本臨床腫瘍学会 2008.03 福岡

  4. 篠崎英司、陳頸松、小林心、久保木泰利、市村崇、尾阪将人、松田正典、小倉真理子、、末永光邦、松阪諭、水沼信之、畠清彦. 消化器がん化学療法中の緊急入院に関する後方視的解析. 第6回日本臨床腫瘍学会 2008.03 福岡

  5. M. Suenaga, N. Mizunuma, E. Shinozaki, S. Matsusaka, K. Chin, K. Kobayashi, Y. Kuboki, Y. Fujiwara, K. Matsueda, K. Hatake.. Doppler ultrasound imaging in management of venous thromboembolic events in patients treated with chemotherapy and bevacizumab.. ASCO Gastrointestinal Cancers Symposium 2008.01

  1. 末永 光邦. 合格のためのサマリーレポートと試験の実際. 日本臨床腫瘍学会第9回教育セミナーAセッション ランチョンセミナー 2007.08.19 パシフィコ横浜 アネックスホール

  2. 松阪 諭, 水沼 信之, 照井 康仁, 三嶋 雄二, 陳 勁松, 末永 光邦, 篠崎 英司, 小倉 真理子, 松田 正典, 市村 崇, 久保木 泰利, 畠 清彦. 転移性大腸癌患者に対する化学療法中の末梢循環癌細胞(Circulating Tumor Cells during Chemotherapy of Metastatic Colorectal Cancer Patients). 日本癌学会総会記事 2007.08.01

  3. 松田正典、松阪諭、庄司大悟、渡邊知映、久保木泰利、市村崇、小倉真理子、末永光邦、陳頸松、水沼信之、畠清彦. FOLFOX療法による末梢神経障害の回復の解析. 第5回日本臨床腫瘍学会 2007.03 札幌

  4. 松阪諭、水沼信之、庄司大悟、渡邊知映、久保木泰利、市村崇、小倉真理子、松田正典、末永光邦、陳頸松、畠清彦. 進行再発大腸癌患者に対するFOLFOX療法後FOLFIRI療法. 第5回日本臨床腫瘍学会 2007.03 札幌

  5. 市村崇、陳頸松、久保木泰利、小倉真理子、松田正典、末永光邦、松阪諭、水沼信之、渡邊知映、畠清彦. 高齢者切除不能進行・再発胃癌に対する全身化学療法. 第5回日本臨床腫瘍学会 2007.03 札幌

  6. 久保木泰利、畠清彦、水沼信之、陳頸松、松阪諭、松田正典、末永光邦、小倉真理子、市村崇、庄司大悟、渡邊知映. 高齢者進行・再発大腸癌に対するFOLFOX4療法の安全性について. 2007.03 札幌

  7. 小倉真理子、陳頸松、市村崇、久保木泰利、松田正典、末永光邦、松阪諭、水沼信之、畠清彦. 胃癌大量腹水貯留症例に対する全身化学療法についての検討. 第5回日本臨床腫瘍学会 2007.03 札幌

  1. Suenaga Mitsukuni, Oya Masatoshi, Ueno Masashi, Yamamoto Jyunji, Yamaguchi Toshiharu, Mizunuma Nobuyuki, Hatake Kiyohiko, Kato Yo, Muto Tetsuichiro. パジェット様進展を伴った肛門管癌 症例報告(Anal Canal Carcinoma with Pagetoid Spread: Report of a Case). Surgery Today 2006.07.01

  1. 篠崎英司、水沼信之、庄司大悟、陳頸松、末永光邦、宇良敬、大矢雅敏、上野雅資、小口正彦、山口俊晴、武藤徹一郎、畠清彦. 進行下部直腸癌に対する術前放射線化学療法・第II相試験における術後補助化学療法の安全性の検討. 第3回日本臨床腫瘍学会 2005.03.01 横浜

  2. 庄司大悟、三嶋裕子、篠崎英司、末永光邦、宇良敬、横山雅大、照井康仁、水沼信之、、陳頸松、高橋俊二、伊藤良則、畠清彦. 外来化学療法処方におけるリスクマネジメント業務. 第3回日本臨床腫瘍学会 2005.03.01 横浜

  1. 斉藤 良太、大山 繁和、末永 光邦、細井則人、竹林隆介、山口 俊晴. 胃癌術前TS-1/CDDP併用療法におけるリンパ節治療効果とCT所見の変化について. 第76回日本胃癌学会総会 2004.03.03 米子

  2. 佐藤貴弘、大山繁和、山口俊晴、瀬戸泰之、末永光邦、上野雅資、大矢雅敏、加藤洋、武藤 徹一郎. 腹部における胃spindle cell tumorの位置付け. 第76回日本胃癌学会総会 2004.03.01

  3. 小菅崇之、大山 繁和、斉藤良太、末永光邦、細井則人、山口俊晴. 胃癌術前TS-1/CDDP併用療法にて組織学的CRが得られた進行胃癌の一例. 第76回日本胃癌学会総会 2004.03.01 米子

  4. 大山繁和、竹林隆介、斉藤良太、末永光邦、椿雅光、瀬戸泰之、馬場哲、陳頸松、薄井明子、山口俊晴. 胃癌化学療法のセーフティーマネージメント. 第76回日本胃癌学会総会 2004.03.01 米子

  5. 竹林隆介、大山繁和、末永光邦、斉藤良太、山口俊晴. 総肝動脈を合併切除し、肝外側区域切除膵頭十二指腸切除にて根治切除出来た進行胃癌の一例. 第76回日本胃癌学会総会 2004.03.01

  6. 末永 光邦、大山繁和、佐藤貴弘、斉藤良太、細井則人、山口俊晴、武藤徹一郎、加藤洋. 残胃の癌における空腸間膜リンパ節転移の検討. 第76回日本胃癌学会総会 2004.03.01 米子

  7. 末永光邦、大矢雅敏、上野雅資、畦倉薫,佐藤貴弘、 大山繁和,山口俊晴,武藤徹一郎,有賀明子、山田恵子、河野敦、木下博勝,加藤洋. 直腸癌の直腸間膜内リンパ節転移に関する造影CTと高解像度MRI、注腸造影の術前診断能の比較. 第60回大腸癌研究会 2004.01.01

  8. 上野雅資、大矢雅敏、畦倉薫,末永光邦、佐藤貴弘、 山口俊晴、武藤徹一郎. 腹腔鏡下手術におけるリンパ節郭清の程度に関する検討. 第60回大腸癌研究会 2004.01.01

  1. Suenaga Mitsukuni, Ohta Kei-ichiro, Toguchi Masataka, Sato Takahiro, Ohyama Shigekazu, Yamaguchi Toshiharu, Muto Tetsuichiro, Yanagisawa Akio, Kato Yo. MALT型リンパ腫領域に発生した胃表現型および腸表現型の高分化型衝突腺癌(Colliding gastric and intestinal phenotype well-differentiated adenocarcinoma of the stomach developing in an area of MALT-type lymphoma). Gastric Cancer 2003.12.01

  2. 佐藤貴弘、上野雅資、大矢雅敏、畦倉薫、太田博俊、末永光邦、山本順司、山口俊晴、細井則人、斉藤良太、武藤徹一郎. 大腸GISTの切除症例の検討. 第58回日本大腸肛門病学会総会 2003.11.01 名古屋

  3. 佐藤貴弘、大山繁和、上野雅資、大矢雅敏、畦倉薫、山口俊晴、瀬戸泰之、末永光邦、細井則人、山田和彦、斉藤良太、古賀倫太郎、阪本良弘、山本順司、武藤徹一郎. 左門脈の5例. 第7回臨床解剖研究会 2003.09.01 横浜

  4. Sato T, Ohyama S,Nagano H,Suenaga M,Yamaguchi T,Muto T. Surgical treatment for gastric lymphoma in cancer institute hospital in Japan. 5th international gastric cancer congress 2003.05.01 Roma

  5. Suenaga M, Ohta K, Sato T, Hosoi N, Ohyama S, Yamaguchi T, Yanagisawa A, Kato Y.. Colliding gastric and intestinal-type well differentiated adenocarcinomas of the stomach an area typically characterized by MALT-type lymphoma.. 5th international gastric cancer congress. 2003.05

  6. 渡邉 利泰、末永光邦、水沼 信之、宇良 敬、陳 頸松、畠 清彦. 当院におけるFOLFOX4療法による末梢神経障害の検討. 第4回日本臨床腫瘍学会 2003.03.18 大阪

  7. 永野秀樹、大山繁和、大平寛典、末永光邦、佐藤貴弘、太田恵一郎、山口俊晴、武藤徹一郎. 胃癌機能温存手術後のQOL評価:患者さんからみたQOL評価. 第75回日本胃癌学会総会 2003.02.01 東京

  8. 永野秀樹、大山繁和、大平寛典、末永光邦、佐藤貴弘、太田恵一郎、山口俊晴、武藤徹一郎. EMR断端陽性例の手術適応について. 第75回日本胃癌学会総会 2003.02.01 東京

  9. 細井則人、大山繁和、佐藤貴弘、末永光邦、大平寛典、太田恵一郎、山口俊晴、奥村栄、中川健、武藤徹一郎. 胃癌術後の肺転移再発に外科切除例の検討. 第75回日本胃癌学会総会 2003.02.01 東京

  10. 佐藤貴弘、大山繁和、永野秀樹、大平寛典、末永光邦、太田恵一郎、山口俊晴、武藤徹一郎、陳頸松、高橋俊二、小口正彦. 当院に於ける胃悪性リンパ腫の治療の近況. 第75回日本胃癌学会総会 2003.02.01 東京

  11. 太田恵一郎、末永光邦、大山繁和、松原敏樹、太田博俊、山口俊晴、武藤徹一郎、中島聰總. 胃癌の腹腔洗浄細胞診の意義と陽性症例に対する治療. 第75回日本胃癌学会総会 2003.02.01 東京

  1. 末永光邦、太田恵一郎、大平寛典、永野秀樹、佐藤貴弘、大山繁和、山口俊晴. 胃癌術後の骨代謝障害発現について. 第32回胃外科・術後障害研究会 2002.12.01 横浜

  2. 大平寛典、大山繁和、末永光邦、永野秀樹、細井則人、佐藤貴弘、太田恵一郎、松原敏樹、太田博俊、山口俊晴. 幽門保存胃切除術のピットフォール. 第32回胃外科・術後障害研究会 2002.12.01 横浜

  3. 佐藤貴弘、大山繁和、永野秀樹、大平寛典、末永光邦、吉田愛、中川彩、太田恵一郎、松原敏樹、山口俊晴、武藤徹一郎、山尾剛一、高橋俊二、小口正彦. 当院に於ける胃悪性リンパ腫の治療. 第32回胃外科・術後障害研究会 2002.12.01 横浜パシフィコ

  1. Keigo Okada, Makiko Saito, Yotaro Motomura, Kota Yoshifuji, Satoru Aoyama, Toshikage Nagao, and Ayako Nogami. FLT3-ITD activates PDK1 which phosphorylates N-Rsk and inhibits Bim to enhance survival in AML cells. The 85th Annual Meeting of the Japanese Society of Hematology 2023.10.13 Tokyo

  2. Yotaro Motomura, Kota Yoshifuji, Daichi Sadato , Ayako Nogami, Makiko Saito, Keigo Okada, Satoru Aoyama, Takehiko Mori, and Toshikage Nagao. Establishment and characterization of TMD13. a novel GCB-type DLBCL cell line. The 63th Annual Meeting of the Japanese Society for Lymphoreticular Tissue Research 2023.06.22 Saitama

  1. Satoru Aoyama, Shunichiro Yasuda, Daisuke Watanabe, Hiroki Akiyama, Yoshihiro Umezawa, Ayako Nogami, Osamu Miura, Norihiko Kawamata. A Novel Protease-Mediated Chimeric Antigen Receptor (CAR) Double-Arm" CAR-T cell system Improves Target Specificity of CAR-T Cell Therapy. The 61st ASH Annual Meeting and Exposition 2019.12.07 Orlando, FL

  1. Yuichi Kumaki. Cancer and gene, cancer and genome. The 32nd lecture open to the public 2018.10.05 Tokyo

  2. Satoru Aoyama, Hiroki Tsushumi, Tatsuya Saito, Masahide Yamamoto, Ken Watanabe, Toshikage Nagao, Tetsuya Fukuda, Norihiko Kawamata, Osamu Miura. Outcome of allogeneic transplantation with FLU/BU4/TBI conditioning regimen for myeloid malignancies. The 40th Annual Meeting of the Japan Society for Hematopoietic Cell Transplantation 2018.02.02 Sapporo

To the head of this page.▲